Akashi DMD drug candidate Fast Tracked


The FDA grants Fast Track designation to Akashi Therapeutics' lead product candidate HT-100 (delayed-release halofuginone) as a potential treatment to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne Muscular Dystrophy (DMD). The agency has also designated HT-100 an Orphan Drug. The product candidate is currently being evaluated in a Phase 1b/2a clinical trial.

Related tickers: (PTCT) (SRPT) (RNA)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs